Navigation Links
Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
Date:3/3/2009

PARIS, March 3 /PRNewswire/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today that its most advanced injectable antibacterial, which combines Novexel's broad spectrum beta lactamase inhibitor, NXL104, with the well established cephalosporin antibiotic, ceftazidime, has entered a second Phase II clinical trial.

This Phase II trial with NXL104/ceftazidime will be in hospitalized patients with complicated intra-abdominal infections (cIAIs). In 2007, Novexel estimates that more than 300,000 patients were treated for cIAIs in hospital in the seven major pharmaceutical markets. This estimate is based on national databases providing hospital patient discharge data.

NXL104/ceftazidime is being developed to treat hospital infections that are caused by Gram negative bacteria, including those resistant to many currently used antibiotics. This Phase II trial is a prospective, multicenter, double-blind, randomized study which is designed to evaluate the efficacy, safety, and tolerability of NXL104/ceftazidime plus metronidazole vs. meropenem (Merrem(R) or Meronem(R), AstraZeneca, NYSE: AZN) in the treatment of adults with cIAIs. Complicated intra-abdominal infections include those infections requiring surgical intervention and which extend beyond the hollow viscus into the peritoneal space. A total of approximately 200 patients will be enrolled, with 100 patients being included in each treatment arm.

The primary objective of the study is to evaluate the clinical response to NXL104/ceftazidime plus metronidazole in the treatment of adult patients with cIAIs as compared to meropenem. This evaluation will be based on the Test of Cure visit two weeks post-therapy. T
'/>"/>

SOURCE Novexel
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novexels NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
4. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
5. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
6. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
7. Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors
8. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
9. New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA
10. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
11. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... WOONSOCKET, R.I. , Aug. 27, 2014  CVS ... has entered into a new clinical affiliation with MedStar ... in Maryland and the ... access to high-quality, affordable health care services for patients. ... to have access to clinical support, medication counseling, chronic ...
(Date:8/27/2014)... , Aug. 27, 2014 Amgen (NASDAQ: ... Drug Administration (FDA) has granted priority review designation for ... Ivabradine is an oral drug that inhibits the ... sinoatrial node, the body,s cardiac pacemaker. 1 Ivabradine ... on myocardial contractility or ventricular repolarization. 1 Heart ...
(Date:8/27/2014)... Aug. 27, 2014  UBM Medica US announces that ... community for medical imaging professionals, presents special reporting about ... Imaging Management,s 2014 Annual Meeting . ... , 11 Principles of Successful Labor Management ... greater profitability. , Why Don,t Patients Know ...
Breaking Medicine Technology:CVS Caremark Announces New Clinical Affiliation with MedStar Health 2CVS Caremark Announces New Clinical Affiliation with MedStar Health 3FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 2FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 3FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 4FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 5FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 6FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 7Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 2Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 3
... 12 American Life League,s historic Personhood ... in adult stem cell research and regenerative ... Deisher, founder and CEO of AVM Biotechnology ... is speaking on over 17 years of ...
... YORK, Jan. 12 The Michael J. Fox Foundation ... two clinical studies that will test drugs already approved ... disease. Because both drugs being tested are already known ... move swiftly toward regulatory approval for use in Parkinson,s ...
Cached Medicine Technology:Stem Cell Pioneer to Speak to A.L.L. Personhood Conference 2Michael J. Fox Foundation Awards $2.9 Million for Two New Parkinson's Disease Clinical Trials 2
(Date:8/27/2014)... National Resident Matching Program International ... Medical Education in Europe (AMEE) Conference being held at ... – September 3, 2014. As an exhibitor, NRMPI ... community, share the benefits of its matching services, and ... in countries throughout the world. , “Exhibiting ...
(Date:8/27/2014)... 28, 2014 Recently, UWDress.com, a popular ... women, has unveiled its new range of elegant ... in this new assortment. All the company's new and ... to 62 percent off. , This experienced company ... corset bridesmaid dresses, simple bridal gowns, backless party outfits, ...
(Date:8/27/2014)... All Canada Goose Parkas from CanadaGooseJackor.nu are ... to modern. With unique detailing such as buttons, leather trim ... step up in opulence. Recently, the company has unveiled its ... 2014. , True enough, the new assortment comes in ... to 28% off) on all these brand new items. By ...
(Date:8/27/2014)... Top 10 Best SEO Hosting, a well-known ... suppliers and announced iPage, Bluehost and GoDaddy are the most ... and Europe to buy useful hosting (including VPS and cloud ... iPage has been serving hosting small business websites ... grown into a leader in the hosting industry for its ...
(Date:8/27/2014)... August 27, 2014 New Jersey’s own ... The Ridgewood County Club during The Barclays – and ... each of the tournament’s four rounds, stepped his way ... Blue Cross Blue Shield of New Jersey (Horizon BCBNSNJ) ... a Wyckoff native playing before family and friends at ...
Breaking Medicine News(10 mins):Health News:National Resident Matching Program International (NRMPI) to Exhibit at the 2014 AMEE Conference 2Health News:Elegant Bridesmaid Dresses For 2014 Now Available At UWDress.com 2Health News:CanadaGooseJackor.nu: 2014 Canada Goose Banff Parkas At Discounted Prices 2Health News:Well-known SEO Hosts Review Site Top10BestSEOHosting.com Recommends iPage, Bluehost and GoDaddy To Webmasters 2Health News:Morgan Hoffmann, PGA TOUR Pro & Wyckoff Native, golfs and walks his way to top 10 finish at The Barclays while raising additional $7,500 for charity 2
... be at play, researchers note , , THURSDAY, May ... suffered fatal cardiac arrest were more likely to have ... survived heart attacks. , But the findings haven,t been ... directly cause any problems. Those who take the drugs ...
... Office of the Vice President of Research at ... its Collaborative Research Seed Grant Program (CRSGP) and ... programs help UTSA faculty establish new, innovative, collaborative ... of UTSA,s five strategic areas of excellence: health, ...
... theft and provides actionable advice to manage, report and ... Search America(R) , a part of Experian and a ... unveiled its Red Flags Rule system designed to help ... Discrepancy Rule from the Federal Trade Commission (FTC). This ...
... Provide Testing Tools to Students taking Board ExamsNEW ... Professional, a leading global provider of information resources ... USMLEasy ( http://www.usmleasy.com ) ... McGraw-Hill that offers institutional access. This innovative testing ...
... care improves level of overall functioning and mental ... suggests a recent Finnish study. , Jorvi Early ... University Central Hospital (HUCH), Jorvi Hospital, Finland, is ... adolescents at risk of developing first-episode psychosis. As ...
... Napa, Calif., (May 14, 2009) Dey, L.P., a ... data from two presentations highlighting the use of Perforomist ... format at the International Conference of the American Thoracic ... , In one analysis, use of Perforomist Inhalation ...
Cached Medicine News:Health News:Psychiatric Drugs Might Raise Cardiac Death Risk 2Health News:UTSA announces funding for new faculty research 2Health News:SearchAmerica(R) Unveils Next-Generation Red Flags Rule System for Health Care 2Health News:SearchAmerica(R) Unveils Next-Generation Red Flags Rule System for Health Care 3Health News:SearchAmerica(R) Unveils Next-Generation Red Flags Rule System for Health Care 4Health News:New Online Institutional Resource in Test Preparation Launched by McGraw-Hill Professional 2Health News:New Online Institutional Resource in Test Preparation Launched by McGraw-Hill Professional 3Health News:Early and network-oriented care may help adolescents at risk of developing psychosis 2Health News:Perforomist Inhalation Solution data to be presented at American Thoracic Society conference 2Health News:Perforomist Inhalation Solution data to be presented at American Thoracic Society conference 3
... for a way to help your patients ... disease? Based on the outcomes of ... (ECP) has improved the quality of their ... normal activities of daily living. , ,MedCath ...
... lab? Worried about the high costs, start-up ... of managing the ongoing business operations? As ... leaving you free to care for your patients., ... convenient diagnostic facility for you and your patients. ...
... currently maintains a large number of mobile, ... in its rental fleet. The labs are ... to several years. The Cath Lab Leasing ... while replacing or upgrading existing equipment, initiating ...
... laser combines excellent cutting, ablation and ... procedures. It is also extremely effective ... stones of all compositions, making it ... its laser light is transmitted through ...
Medicine Products: